Cary P. Gross, MD

home / authors / cary-p-gross-md

Articles

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

Kevin W. Su, MD;Cary P. Gross, MD;Nicholas S. Downing, MD;Kerin B. Adelson, MD;Joseph S. Ross, MD, MHS

July 28th 2017

Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Simon P. Kim, MD, MPH;Cary P. Gross, MD;Quoc-Dien Trinh, MD;Marc C. Smaldone, MD, MSHP;R. Houston Thompson, MD;Sarah P. Psutka, MD;Holly Van Houten, BA;Leona C. Han, BA;Robert Abouassaly, MD

February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.